IQVIA Holdings Inc. (IQV)
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. IQVIA has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
|IPO Date||May 9, 2013|
|Industry||Life Sciences Tools & Services|
4820 Emperor Blvd
Durham, North Carolina 27703-8426
|Phone||919 998 2000|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Ari Bousbib||Chairman, President and Chief Executive Officer|
|Ronald E. Bruehlman||Executive Vice President and Chief Financial Officer|
|Kevin C. Knightly||President of Technology and Commercial Solutions|
|Eric M. Sherbet||Executive Vice President, General Counsel and Secretary|
|W. Richard Staub III||President of Research & Development Solutions|
|Emmanuel N. Korakis||Senior Vice President, Corporate Controller and Principal Accounting Officer|
|Dr. Jeffrey A. Spaeder||Senior Vice President, Global Chief Medical and Scientific Officer|
|Alejandro Martinez||Chief Information Officer|
|Andrew Markwick||Senior Vice President of Investor Relations and Treasury|
|Nicholas Childs||Senior Vice President, Investor Relations and Corporate Communications|
Latest SEC Filings
|Dec 23, 2021||4||Statement of changes in beneficial ownership of securities|
|Dec 3, 2021||4||Statement of changes in beneficial ownership of securities|
|Dec 1, 2021||4||Statement of changes in beneficial ownership of securities|
|Oct 22, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Oct 21, 2021||8-K||Current report|
|Aug 25, 2021||8-K||Current report|
|Aug 18, 2021||4||Statement of changes in beneficial ownership of securities|
|Aug 5, 2021||4||Statement of changes in beneficial ownership of securities|
|Jul 28, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Jul 27, 2021||8-K||Current report|
|View All SEC Filings|